SMMT Summit Therapeutics Inc.

Summit Therapeutics Inc.

Biotechnology: Pharmaceutical Preparations

Health Care

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

IPO Year: 2015

Exchange: NASDAQ

Website: summittxinc.com

Recent Analyst Ratings for Summit Therapeutics Inc.

Date	Price Target	Rating	Analyst
6/11/2025	$12.00	Underperform	Leerink Partners
3/26/2025	$23.00 → $35.00	Neutral → Buy	Citigroup
3/21/2025		Overweight	Cantor Fitzgerald
3/12/2025	$30.00	Outperform	Evercore ISI
2/28/2025	$42.00	Buy	Goldman
1/8/2025	$35.00	Buy	Truist
12/11/2024	$30.00	Overweight	Wells Fargo
12/6/2024	$31.00	Buy	Jefferies
11/4/2024	$32.00	Mkt Outperform	JMP Securities
9/27/2024	$19.00 → $23.00	Buy → Neutral	Citigroup

See more ratings

Summit Therapeutics Inc.

Recent Analyst Ratings for Summit Therapeutics Inc.

Summit Therapeutics Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Zanganeh Mahkam bought $411,094 worth of shares (110,321 units at $3.73), increasing direct ownership by 5% to 520,814 units (SEC Form 4)

Dhingra Ankur bought $375,000 worth of shares (100,000 units at $3.75) (SEC Form 4)

Zanganeh Mahkam exercised 805,495 in-the-money shares at a strike of $1.49 and bought $10,350 worth of shares (5,000 units at $2.07) (SEC Form 4)

Dhingra Ankur bought $44,254 worth of shares (20,400 units at $2.17) (SEC Form 4)

Soni Manmeet Singh bought $4,999,999 worth of shares (2,976,190 units at $1.68) (SEC Form 4)

Summit Therapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Co-Chief Executive Officer Zanganeh Mahkam exercised 74,545 shares at a strike of $2.64 (SEC Form 4)

Co-Chief Executive Officer Duggan Robert W exercised 74,545 shares at a strike of $2.64, increasing direct ownership by 0.01% to 555,754,696 units (SEC Form 4)

SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

SEC Form 4 filed by COO and CFO Soni Manmeet Singh

SEC Form 4 filed by Co-Chief Executive Officer Duggan Robert W

SEC Form 4 filed by Co-Chief Executive Officer Zanganeh Mahkam

Co-Chief Executive Officer Zanganeh Mahkam exercised 3,985,055 in-the-money shares at a strike of $1.58 (SEC Form 4)

Co-Chief Executive Officer Duggan Robert W exercised 3,985,055 in-the-money shares at a strike of $1.58, increasing direct ownership by 0.72% to 555,680,151 units (SEC Form 4)

SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

SEC Form 4 filed by Co-Chief Executive Officer Duggan Robert W